Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitae’s Debt Financing Braves Renin Inhibitor Risk, FDA Wariness In Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

Two lenders wade in despite harsh credit environment for biotechs.

You may also be interested in...



Second Collaboration With Boehringer Provides Extended Cash Runway For Vitae

Previously partnered on a diabetes program, the two companies now will collaborate on a BACE inhibitor will potential as a disease-altering therapy in Alzheimer’s.

Second Collaboration With Boehringer Provides Extended Cash Runway For Vitae

Previously partnered on a diabetes program, the two companies now will collaborate on a BACE inhibitor will potential as a disease-altering therapy in Alzheimer’s.

Novartis Plans To Buy Back Speedel For $880 Million

Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.

Topics

UsernamePublicRestriction

Register

PS067085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel